following an abbreviated submission:
upadacitinib (Rinvoq®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.
Upadacitinib offers an additional treatment choice in the therapeutic class of selective immunosuppressants in this setting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice636KB (PDF)
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2575
- Indication:
Treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response or, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 June 2023